MaxCyte joins the alliance for mRNA Medicines as a founding member

MaxCyte announced that it has joined the Alliance for mRNA Medicines, AMM, as a founding member. AMM is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health and society. “We proudly join our colleagues in advancing AMM’s mission as we recognize the significant potential of mRNA scientific innovation to transform human health,” said Doug Doerfler, President and CEO of MaxCyte. “Our versatile, leading electroporation platform continues to provide scientific innovators with a powerful and flexible transfection method to accelerate the development of critical medicines and vaccines. We remain steadfast in our commitment to enable development of new applications for mRNA technology.”